Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma

Clinical Radiology

Volumn 63, Issue 7, 2008, Pages 765-773

  Salahudeen, H M ^a   Balan, A ^a   Naik, K ^a   Mirsadraee, S ^a   Scarsbrook, A F ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CHI SQUARE TEST; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; FISHER EXACT TEST; HISTOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; METASTASIS; PATIENT CARE; PREDICTIVE VALIDITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44749093214     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2008.02.002     Document Type: Article

References (37)

1. Liberale G., Van Laethem J.L., Gay F., et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 30 (2004) 942-947
2. Farrokh D., and Barry A.S. Neoplasms of the esophagus and stomach. Semin Nucl Med 34 (2004) 198-208
3. Munden R.F., Macapinlac H.A., and Eramus J.J. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 21 (2006) 137-145
4. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 3 (1995) 537-547
5. Stahl A., Stollfuss J., Ott K., et al. FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET findings. Nuklearmedizin 44 6 (2005) 249-255 [quiz N55-6]
6. Yuan S., Yu Y., Chao K.S., et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47 (2006) 1255-1259
7. Green F.L., and American Joint Committee on Cancer (AJCC). In: Green F.L., Page D.L., Fleming I.D., et al. (Eds). Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York
8. 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
9. Choi J.Y., Lee K.H., Shim Y.M., et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG-PET. J Nucl Med 41 (2000) 808-815
10. Bar-Shalom R., Guralnik L., Tsalic M., et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32 (2005) 918-924
11. Flanagan F.L., Dehdashti F., Siegel B.A., et al. Staging of esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168 (1997) 417-424
12. Rankin S., Taylor H., Cook G., et al. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol 53 (1998) 659-665
13. McAteer D., Wallis F., Couper G., et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72 (1999) 525-529
14. Meltzer C.C., Luketich J.D., Friedman D., et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 25 (2000) 882-887
15. Wren S.M., Stijns P., and Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 137 (2002) 1001-1006
16. Himeno S., Yasuda S., Shimada H., et al. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 32 (2002) 340-346
17. Rasanen J.V., Sihvo E.I., and Knuuti M.J. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10 (2003) 954-960
18. Heeren P.A., Jager P.L., Bongaerts F., et al. Detection of distant metastases in esophageal cancer with (18)F-FDG-PET. J Nucl Med 45 (2004) 980-987
19. Lerut T., Coosemans W., Decker G., et al. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol 10 (2001) 113-122
20. Hossein J., Robert W.H., and Peter S.C. 2-Deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol 8 (2006) 193-200
21. Yeung H.W., Macapinlac H.A., Mazumdar M., et al. Incremental value over computed tomography. Clin Positron Imaging 2 (1999) 255-260
22. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18 (2000) 3202-3210
23. Lerut T., Flamen P., Ectors N., et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232 (2000) 743-752
24. Imdahl A., Hentschel M., Kleimaier M., et al. Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg 389 (2004) 283-288
25. Kole A.C., Plukker J.T., Nieweg O.E., et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78 (1998) 521-527
26. Luketich J.D., Friedman D.M., Weigel T.L., et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 68 (1999) 1133-1136 [discussion: 1136-7]
27. Fukunaga T., Okazumi S., Koide Y., et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39 (1998) 1002-1007
28. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 45 (2004) 1843-1850
29. Voormolen M.H.J., Van Deelen R.A.J., Tilanus H.W., et al. Esophageal carcinoma and multiple primary tumors. Dis Esophagus 8 (1995) 218-221
30. Kagei K., Hosokawa M., Shirato H., et al. Efficacy of intense screening and treatment for synchronous second primary cancers in patients with esophageal cancer. Jpn J Clin Oncol 32 (2002) 120-127
31. 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 46 (2005) 1321-1325
32. Graham M.M., Peterson L.M., and Hayward R.M. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27 (2000) 647-655
33. Ahuja V., Coleman R.E., Herndon J., et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83 (1998) 918-924
34. Oshida M., Uno K., Suzuki M., et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 82 (1998) 2227-2234
35. Oyama N., Akino H., Suzuki Y., et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 4 (2002) 99-104
36. van Westreenen H.L., Plukker J.T.M., Cobben D.C.P., et al. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 185 (2005) 436-440
37. Taira A.V., Herfkens R.J., Ghambhir S.S., et al. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology 243 (2007) 204-211